Published: Guidance, quality standards and advice
Showing 1 to 2 of 2
| Title | Reference number | Published | Last updated |
|---|---|---|---|
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | TA1097 | ||
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 |